Takeover

CLYMClimb Bio, Inc.

Pharmaceutical Preparations

Revenue
—
Operating margin
—
EBITDA
−$68MFY2021: −$36MFY2022: −$45MFY2023: −$40MFY2024: −$82MFY2025: −$68M
17% YoY
Market cap
$589M
Employees
70,000
Net debt / EBITDA
—
AI in 10-K
0.3
mentions per 10K words

Takeover score 3 of 13

Fixable underperformance 0 of 7

Buyer economics 2 of 4

Catalysts 1 of 2

Financials

MetricFY2021FY2022FY2023FY2024FY2025YoYTrend
Operating income−$36M−$45M−$40M−$82M−$68M 17% FY2021: −$36MFY2022: −$45MFY2023: −$40MFY2024: −$82MFY2025: −$68M
Net income−$47M−$45M−$35M−$74M−$60M 19% FY2021: −$47MFY2022: −$45MFY2023: −$35MFY2024: −$74MFY2025: −$60M
Operating cash flow−$36M−$37M−$21M−$16M−$54M 249% FY2021: −$36MFY2022: −$37MFY2023: −$21MFY2024: −$16MFY2025: −$54M
Capex——$0$0$186KFY2023: $0FY2024: $0FY2025: $186K
Stock-based comp$4M$7M$13M$6M$8M 45% FY2021: $4MFY2022: $7MFY2023: $13MFY2024: $6MFY2025: $8M

Deal filings

FiledFormAcquirerPricePremium
Jun 4, 2024DEFM14ATenet Medicines, Inc.$3.8415.4%
May 17, 2024PREM14AEliem Therapeutics, Inc.$3.8415.4%

13D filers

FiledFilerFormStakeIntent
Jul 7, 2026RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13D/A33.0%Passive
Apr 29, 2026RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13D/A33.0%Active
Dec 15, 2025RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13D/A33.0%Active
Oct 16, 2025AI ETI LLCSCHEDULE 13D/A0.0%Passive
Oct 7, 2025AI ETI LLCSCHEDULE 13D/A5.7%Passive
Aug 16, 2024AI ETI LLCSC 13D/A7.5%Passive
Jul 1, 2024RA CAPITAL MANAGEMENT, L.P.SC 13D/A47.1%Active
Jun 6, 2024RA CAPITAL MANAGEMENT, L.P.SC 13D/A44.3%Active
May 17, 2024AI ETI LLCSC 13D/A17.2%Passive
May 17, 2024RA CAPITAL MANAGEMENT, L.P.SC 13D/A45.3%Active

Insider trading

Open-market buys, 12 mo
$780K · 3
Open-market sells, 12 mo
$3M · 6
Net
−$2M

Pay vs performance

No pay-versus-performance disclosure yet.